Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-34157432
2.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-33984311

RESUMO

Ischemic events are the most serious complications of facial antiaging treatment with dermal fillers. Ischemia can cause Nicolau syndrome, blindness, or even stroke. This article discusses how to prevent ischemic complications and what steps to take should a dermatologic emergency develop. A thorough understanding of facial anatomy is important. Preferred procedural techniques involve the use of cannulas and retrograde injection. When ischemia is detected in the skin, hyaluronidase should be injected, preferably through a cannula. If ocular ischemia occurs, the patient should be transferred to a hospital with stroke code activation.

4.
Br J Dermatol ; 183(1): 71-77, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32348545

RESUMO

BACKGROUND: The cutaneous manifestations of COVID-19 disease are poorly characterized. OBJECTIVES: To describe the cutaneous manifestations of COVID-19 disease and to relate them to other clinical findings. METHODS: We carried out a nationwide case collection survey of images and clinical data. Using a consensus we described five clinical patterns. We later described the association of these patterns with patient demographics, the timing in relation to symptoms of the disease, the severity and the prognosis. RESULTS: The lesions may be classified as acral areas of erythema with vesicles or pustules (pseudo-chilblain) (19%), other vesicular eruptions (9%), urticarial lesions (19%), maculopapular eruptions (47%) and livedo or necrosis (6%). Vesicular eruptions appear early in the course of the disease (15% before other symptoms). The pseudo-chilblain pattern frequently appears late in the evolution of the COVID-19 disease (59% after other symptoms), while the rest tend to appear with other symptoms of COVID-19. The severity of COVID-19 shows a gradient from less severe disease in acral lesions to more severe in the latter groups. The results are similar for confirmed and suspected cases, in terms of both clinical and epidemiological findings. Alternative diagnoses are discussed but seem unlikely for the most specific patterns (pseudo-chilblain and vesicular). CONCLUSIONS: We provide a description of the cutaneous manifestations associated with COVID-19 infection. These may help clinicians approach patients with the disease and recognize cases presenting with few symptoms. What is already known about this topic? Previous descriptions of cutaneous manifestations of COVID-19 were case reports and mostly lacked illustrations. What does this study add? We describe a large, representative sample of patients with unexplained skin manifestations and a diagnosis of COVID-19, using a consensus method to define morphological patterns associated with COVID-19. We describe five clinical patterns associated with different patient demographics, timing and prognosis, and provide illustrations of these patterns to allow for easy recognition.


Assuntos
Betacoronavirus/patogenicidade , Consenso , Infecções por Coronavirus/complicações , Pneumonia Viral/complicações , Dermatopatias Virais/classificação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , COVID-19 , Criança , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/virologia , Dermatologistas/estatística & dados numéricos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pandemias , Pneumonia Viral/diagnóstico , Pneumonia Viral/epidemiologia , Pneumonia Viral/virologia , Prognóstico , Estudos Prospectivos , SARS-CoV-2 , Dermatopatias Virais/diagnóstico , Dermatopatias Virais/virologia , Espanha/epidemiologia , Inquéritos e Questionários/estatística & dados numéricos , Terminologia como Assunto , Fatores de Tempo , Adulto Jovem
6.
Actas Dermosifiliogr (Engl Ed) ; 111(1): 47-52, 2020 Jan 02.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31627850

RESUMO

OBJECTIVES: To analyze trends in the prevalence of contact sensitization to p-phenylenediamine between 2004 and 2014, taking into consideration that the concentration of this product in cosmetics was regulated in 2009. To explore risk factors for contact allergy to p-phenylenediamine. MATERIAL AND METHODS: Retrospective observational study of patients suspected of having contact dermatitis from allergy to p-phenylenediamine during the years between 2004 and 2015 in 8 tertiary level hospitals. The patients underwent patch testing (TRUE-test) with the standard series of the Spanish Research Group on Contact Dermatitis and Skin Allergies. This series included p-phenylenediamine 1%. We followed international recommendations for the statistical analysis of data related to contact allergies. RESULTS: Three hundred eighty-six out of 9341 patients (4.1%) had positive reactions to p-phenylenediamine. The prevalence tended to decrease in the early years (2004-2007) and then leveled off at around 4%. Risk factors for developing contact dermatitis from p-phenylenediamine were sex, age over 40 years, multiple sensitivities, and profession, notably workers in hair salons and those who handle rubber and plastics. CONCLUSIONS: The prevalence of p-phenylenediamine allergy remains high among patients with contact eczema. Risk factors for p-phenylenediamine contact allergy are consistent with previous reports.


Assuntos
Corantes/efeitos adversos , Dermatite Alérgica de Contato/epidemiologia , Dermatite Alérgica de Contato/etiologia , Fenilenodiaminas/efeitos adversos , Adulto , Feminino , Humanos , Masculino , Prevalência , Estudos Retrospectivos , Fatores de Risco , Espanha/epidemiologia
8.
Actas Dermosifiliogr ; 108(10): 924-930, 2017 Dec.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-28803615

RESUMO

INTRODUCTION AND OBJECTIVES: The Early Arthritis for Psoriatic patients (EARP) questionnaire is a screening tool for psoriatic arthritis. The original Italian version has good measurement properties but the EARP required translation and adaptation for use in Spain. This article describes the cultural adaptation process as a step prior to validation. MATERIAL AND METHODS: We used the principles of good practice for the cross-cultural adaptation of patient-reported outcomes measurement established by the International Society Pharmacoeconomics and Outcome Research. The steps in this process were preparation, forward translation, reconciliation, back-translation and review, harmonization, cognitive debriefing and review, and proofreading. During preparation the developers of the original questionnaire were asked for their permission to adapt the EARP for use in Spain and to act as consultants during the process. RESULTS: The original questionnaire was translated into Spanish by native Spanish translators, who made slight changes that were approved by the questionnaire's developers. The Spanish version was then back-translated into Italian; that version was reviewed to confirm equivalence with the original Italian text. The reconciled Spanish EARP was then tested for comprehensibility and interpretation in a group of 35 patients. All the patients answered all items without making additional comments. CONCLUSION: This cultural adaptation of the EARP questionnaire for Spanish populations is the first step towards its later use in routine clinical practice. The application of a cross-cultural adaptation method ensured equivalence between the original and Spanish versions of the EARP. The Spanish questionnaire will be validated in a second stage.


Assuntos
Artrite Psoriásica/diagnóstico , Inquéritos e Questionários , Adulto , Idoso , Características Culturais , Assistência à Saúde Culturalmente Competente , Diagnóstico Precoce , Escolaridade , Feminino , Humanos , Idioma , Masculino , Pessoa de Meia-Idade , Espanha , Traduções
9.
Actas Dermosifiliogr ; 107(7): 559-66, 2016 Sep.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-27262363

RESUMO

The Spanish standard patch test series, as recommended by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC), has been updated for 2016. The new series replaces the 2012 version and contains the minimum set of allergens recommended for routine investigation of contact allergy in Spain from 2016 onwards. Four haptens -clioquinol, thimerosal, mercury, and primin- have been eliminated owing to a low frequency of relevant allergic reactions, while 3 new allergens -methylisothiazolinone, diazolidinyl urea, and imidazolidinyl urea- have been added. GEIDAC has also modified the recommended aqueous solution concentrations for the 2 classic, major haptens methylchloroisothiazolinone and methylisothiazolinone, which are now to be tested at 200ppm in aqueous solution, and formaldehyde, which is now to be tested in a 2% aqueous solution. Updating the Spanish standard series is one of the functions of GEIDAC, which is responsible for ensuring that the standard series is suited to the country's epidemiological profile and pattern of contact sensitization.


Assuntos
Dermatite Alérgica de Contato/diagnóstico , Testes do Emplastro/normas , Dermatite Alérgica de Contato/epidemiologia , Humanos , Espanha/epidemiologia
13.
Actas Dermosifiliogr ; 106 Suppl 1: 60-6, 2015 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-26895940

RESUMO

Nail diseases are a diagnostic challenge and high-frequency ultrasound with colour Doppler is a simple and painless diagnostic test that can often be useful. Ultrasound allows real-time evaluation of the anatomical structures of the nail and its vascularisation. The present study reviews the literature on ultrasound findings in the normal nail and in inflammatory and tumoural disease.


Assuntos
Doenças da Unha/diagnóstico por imagem , Ultrassonografia , Humanos , Doenças da Unha/terapia , Unhas/diagnóstico por imagem
15.
Actas Dermosifiliogr ; 105(7): 663-74, 2014 Sep.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-24726043

RESUMO

Photodynamic therapy (PDT) is an option for the treatment of actinic keratosis, Bowen disease, and certain types of basal cell carcinoma. It is also used to treat various other types of skin condition, including inflammatory and infectious disorders. The main disadvantages of PDT are the time it takes to administer (both for the patient and for health professionals) and the pain associated with treatment. Daylight-mediated PDT has recently been reported to be an alternative to the conventional approach. Several studies have shown it to be similar in efficacy to and better tolerated than classic PDT for the treatment of mild to moderate actinic keratosis. Nevertheless, most of these studies are from northern Europe, and no data have been reported from southern Europe. The present article reviews the main studies published to date, presents the treatment protocol, and summarizes our experience with a group of treated patients.


Assuntos
Fotoquimioterapia , Dermatopatias/terapia , Humanos , Fotoquimioterapia/efeitos adversos , Fotoquimioterapia/métodos , Espanha , Inquéritos e Questionários
17.
Actas Dermosifiliogr ; 105(1): 74-7, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24378421

RESUMO

INTRODUCTION: Notalgia paresthetica is a sensory mononeuropathy that affects dorsal segments T2 to T6. It can have a significant effect on quality of life. Numerous treatments have been used with variable results. MATERIAL AND METHODS: Five patients diagnosed with notalgia paresthetica were treated with intradermal botulinum toxin A. None had achieved relief of the pruritus with previous treatments. RESULTS: Variable results were observed after the administration of intradermal botulinum toxin. Complete resolution of the pruritus was not achieved in any of the patients. CONCLUSIONS: Botulinum toxin A appears to be a safe therapeutic option for patients with notalgia paresthetica. However, data currently available come from small patient series, making it difficult to draw definitive conclusions regarding the true efficacy and long-term effects of this treatment.


Assuntos
Toxinas Botulínicas Tipo A/uso terapêutico , Hiperpigmentação/complicações , Neuralgia/tratamento farmacológico , Parestesia/tratamento farmacológico , Prurido/tratamento farmacológico , Corticosteroides/uso terapêutico , Toxinas Botulínicas Tipo A/administração & dosagem , Capsaicina/uso terapêutico , Carbamazepina/análogos & derivados , Carbamazepina/uso terapêutico , Terapia Combinada , Avaliação de Medicamentos , Feminino , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Injeções Intradérmicas , Masculino , Pessoa de Meia-Idade , Neuralgia/complicações , Oxcarbazepina , Parestesia/complicações , Parestesia/terapia , Modalidades de Fisioterapia , Pregabalina , Prurido/complicações , Prurido/terapia , Ombro , Estimulação Elétrica Nervosa Transcutânea , Resultado do Tratamento , Ácido gama-Aminobutírico/análogos & derivados , Ácido gama-Aminobutírico/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA